|
1
|
Simon K: Colorectal cancer development and
advances in screening. Clin Interv Aging. 11:967–976. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Jakubowski CD, Fedewa SA, Davis
A and Azad NS: Colorectal cancer in the young: Epidemiology,
prevention, management. Am Soc Clin Oncol Educ Book. 40:1–14.
2020.PubMed/NCBI
|
|
4
|
Tang X, Peng J, Huang S, Xu H, Wang P,
Jiang J, Zhang W, Shi X, Shi L, Zhong X and Lü M: Global burden of
early-onset colorectal cancer among people aged 40–49 years from
1990 to 2019 and predictions to 2030. J Cancer Res Clin Oncol.
149:16537–16550. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017.PubMed/NCBI
|
|
6
|
Yiu AJ and Yiu CY: Biomarkers in
colorectal cancer. Anticancer Res. 36:1093–1102. 2016.PubMed/NCBI
|
|
7
|
De Rosa M, Pace U, Rega D, Costabile V,
Duraturo F, Izzo P and Delrio P: Genetics, diagnosis and management
of colorectal cancer (Review). Oncol Rep. 34:1087–1096. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chakedis J and Schmidt CR: Surgical
treatment of metastatic colorectal cancer. Surg Oncol Clin N Am.
27:377–399. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Scaringi S, Kianmanesh R, Sabate JM,
Facchiano E, Jouet P, Coffin B, Parmentier G, Hay JM, Flamant Y and
Msika S: Advanced gastric cancer with or without peritoneal
carcinomatosis treated with hyperthermic intraperitoneal
chemotherapy: A single western center experience. Eur J Surg Oncol.
34:1246–1252. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Surmont VF and van Meerbeeck JP:
Raltitrexed in mesothelioma. Expert Rev Anticancer Ther.
11:1481–1490. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ding WX, Liu S, Ma JX, Pu J, Wang HJ,
Zhang S and Sun XC: Raltitrexed increases radiation sensitivity of
esophageal squamous carcinoma cells. Cancer Cell Int. 19:362019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Deboever G, Hiltrop N, Cool M and
Lambrecht G: Alternative treatment options in colorectal cancer
patients with 5-fluorouracil- or capecitabine-induced
cardiotoxicity. Clin Colorectal Cancer. 12:8–14. 2013.PubMed/NCBI
|
|
13
|
Liu Y, Wu W, Hong W, Sun X, Wu J and Huang
Q: Raltitrexed-based chemotherapy for advanced colorectal cancer.
Clin Res Hepatol Gastroenterol. 38:219–225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baidoun F, Elshiwy K, Elkeraie Y, Merjaneh
Z, Khoudari G, Sarmini MT, Gad M, Al-Husseini M and Saad A:
Colorectal Cancer Epidemiology: Recent Trends and Impact on
Outcomes. Curr Drug Targets. 22:998–1009. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li J, Ma X, Chakravarti D, Shalapour S and
DePinho RA: Genetic and biological hallmarks of colorectal cancer.
Genes Dev. 35:787–820. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Haraldsdottir S, Einarsdottir HM,
Smaradottir A, Gunnlaugsson A and Halfdanarson TR: Colorectal
cancer-review. Laeknabladid. 100:75–82. 2014.(In Icelandic).
PubMed/NCBI
|
|
17
|
Li L, Wang Y, Huang X, Sun J and Zhang J.:
Effect of xiaoyutang combined with intraperitoneal heat perfusion
chemotherapy on immune function, circulating mir, prognosis, and
survival of postoperative patients with colorectal cancer. Comput
Math Methods Med. 2021:16198092021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhou HT, Jiang J, Guan X, Su H, Liang JW,
Pei W, Wang Z, Liu Z, Jiang Z, Liu Q, et al: The short-term effect
analysis of intraoperative intraperitoneal perfusion chemotherapy
with lobaplatin for colorectal cancer. J BUON. 24:442–448.
2019.PubMed/NCBI
|
|
19
|
McCabe-Lankford E, Peterson M, McCarthy B,
Brown AJ, Terry B, Galarza-Paez L and Levi-Polyachenko N: Murine
models of intraperitoneal perfusion for disseminated colorectal
cancer. J Surg Res. 233:310–322. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ceelen WP and Flessner MF: Intraperitoneal
therapy for peritoneal tumors: Biophysics and clinical evidence.
Nat Rev Clin Oncol. 7:108–115. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ceelen W, Braet H, van Ramshorst G,
Willaert W and Remaut K: Intraperitoneal chemotherapy for
peritoneal metastases: An expert opinion. Expert Opin Drug Deliv.
17:511–522. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Batra A, Rigo R, Hannouf MB and Cheung WY:
Real-world safety and efficacy of raltitrexed in patients with
metastatic colorectal cancer. Clin Colorectal Cancer. 20:e75–e81.
2021.PubMed/NCBI
|
|
23
|
Blondy S, David V, Verdier M, Mathonnet M,
Perraud A and Christou N: 5-Fluorouracil resistance mechanisms in
colorectal cancer: From classical pathways to promising processes.
Cancer Sci. 111:3142–3154. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li S, Li X, Zhu Q, Gao J, Zhu C and Zhu L:
Raltitrexed chemotherapy regimen plus bevacizumab as second-line
treatment for metastatic colorectal cancer: A prospective
multicenter phase II trial. Cancer Control.
31:107327482412750122024. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Cheng Y, Teng Z, Zhang Y, Jin B, Zheng Z,
Man L, Wang Z, Teng Y, Yu P, Shi J, et al: Irinotecan plus
raltitrexed as second-line treatment in locally advanced or
metastatic colorectal cancer patients: A prospective open-label,
single-arm, multi-center, phase II study. BMC Cancer. 24:10822024.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kelly C, Bhuva N, Harrison M, Buckley A
and Saunders M: Use of raltitrexed as an alternative to
5-fluorouracil and capecitabine in cancer patients with cardiac
history. Eur J Cancer. 49:2303–2310. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen L, He Y, Chen H and Cheng J: Combined
impact of inflammation, nutrition, and cardiovascular health on
cancer survivor mortality: A retrospective NHANES cohort analysis
(2005–2018). Expert Rev Anticancer Ther. 25:1459–1469. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li K, Chen Y, Zhang Z, Wang K, Sulayman S,
Zeng X, Ababaike S, Guan J and Zhao Z: Preoperative
pan-immuno-inflammatory values and albumin-to-globulin ratio
predict the prognosis of stage I–III colorectal cancer. Sci Rep.
15:115172025. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li KJ, Zhang ZY, Wang K, Sulayman S, Zeng
XY, Liu J, Chen Y and Zhao ZL: Prognostic scoring system using
inflammation- and nutrition-related biomarkers to predict prognosis
in stage I–III colorectal cancer patients. World J Gastroenterol.
31:1045882025.PubMed/NCBI
|
